

AMENDMENT

In the Claims:

Please cancel claims 1-5 and 16-71, presently pending, and substitute the following

claims:

72. (New) A method of modulating cells that express 19P1E8, the method comprising:

administering to the cells an altering composition, whereby the composition alters the status of 19P1E8 or alters the status of a molecule that is modulated by 19P1E8, whereby cells that express 19P1E8 are modulated.

73. (New) A method in accordance with claim 72 wherein said modulating results in inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said cells an antibody or fragment thereof both of which specifically bind to an 19P1E8 protein,

whereby cells that express 19P1E8 are modulated by virtue of the growth or survival of cancer cells that express 19P1E8 being inhibited.

74. (New) A method in accordance with claim 72 wherein said modulating results in inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said cells a vector that encodes an antibody or fragment thereof both of which immunospecifically bind to an 19P1E8 protein,

whereby cells that express 19P1E8 are modulated by virtue of the growth or survival of cancer cells that express 19P1E8 being inhibited..

75. (New) A method of claim 74 further comprising a step of: releasing antibody from cells that express the antibody.

76. (New) A method of claim 73:

wherein said antibody is a single chain monoclonal antibody.

BEST AVAILABLE COPY

77. (New) A method in accordance with claim 72 wherein said modulating results in inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said cells a ribozyme that cleaves RNA essential for expression of 19P1E8,

whereby cells that express 19P1E8 are modulated by virtue of the growth or survival of cancer cells that express 19P1E8 being inhibited.

78. (New) A method in accordance with claim 72 wherein said modulating results in inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said cells an antisense polynucleotide to an RNA essential for expression of 19P1E8,

whereby cells that express 19P1E8 are modulated by virtue of the growth or survival of cancer cells that express 19P1E8 being inhibited.

79. (New) A method in accordance with claim 72 wherein said modulating results in inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said cells a substance that inhibits the secretion of 19P1E8 from said cells,

whereby said cells that express 19P1E8 are modulated by virtue of the growth or survival of cancer cells that express 19P1E8 being inhibited.

80. (New) A method treating a subject comprising cells that express 19P1E8 by modulating said cells, the method comprising:

administering to the cells an altering composition, whereby the composition alters the status of 19P1E8 or alters the status of a molecule that is modulated by 19P1E8,

whereby cells that express 19P1E8 are modulated and the subject receives some treatment effect.

81. (New) A method in accordance with claim 80 wherein said treating is effected by inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said subject an antibody or fragment thereof both of which specifically bind to an 19P1E8 protein,

whereby cells that express 19P1E8 are modulated by virtue of the growth or survival of cancer cells that express 19P1E8 being inhibited.

82. (New) A method in accordance with claim 80 wherein said treating is effected by inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said subject a vector that encodes an antibody or fragment thereof both of which immunospecifically binds to an 19P1E8 protein,

whereby cells that express 19P1E8 are modulated by virtue of the growth or survival of cancer cells that express 19P1E8 being inhibited..

83. (New) A method of claim 82 further comprising a step of:
releasing antibody from cells that express the antibody.

84. (New) The method of claim 82, wherein said antibody is a single chain monoclonal antibody.

85. (New) A method in accordance with claim 80 wherein said treating is effected by inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said subject a ribozyme that cleaves RNA essential for expression of 19P1E8,

whereby cells that express 19P1E8 are modulated by virtue of the growth or survival of cancer cells that express 19P1E8 being inhibited.

86. (New) A method in accordance with claim 80 for inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said subject an antisense polynucleotide,

whereby cells that express 19P1E8 are modulated by virtue of the growth or survival of cancer cells that express 19P1E8 being inhibited.

87. (New) A method in accordance with claim 80 for inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said subject a substance that inhibits the secretion of 19P1E8 from said cells,

whereby said cells that express 19P1E8 are modulated by virtue of the growth or survival of cancer cells that express 19P1E8 being inhibited.

88. (New) A method in accordance with claim 80 wherein said treating is effected by inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said subject an 19P1E8 protein,

whereby an immune response if generated, and

whereby said cells that express 19P1E8 are modulated by virtue of the growth or survival of cancer cells that express 19P1E8 being inhibited.

89. (New) A method in accordance with claim 80 wherein said treating is effected by inhibiting growth or survival of cancer cells that express 19P1E8:

wherein the administering step comprises administering to said cells a vector that comprises a polynucleotide comprising an 19P1E8 protein coding sequence,

whereby an immune response if generated, and

whereby said cells that express 19P1E8 are modulated by virtue of the growth or survival of cancer cells that express 19P1E8 being inhibited.